Effect of Prednisolone treatment in Mycoplasma pneumoniae in children

Effect of Prednisolone treatment in Mycoplasma pneumoniae in children - Effect of Prednisolone treatment in Mycoplasma pneumoniae in children

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010574

Enrollment

Registered

2013-06-01

Start date

2013-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mycoplasma pneumoniae

Interventions

1.Steroid use group Drug:Prednisolone Way of administration:oral administration(PSL 1mg/kg/day for 3days)or intravenous injection(PSL 1.5mg/kg 3times/day for 3days) 2.Steroid not use group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: mild or moderate Mycoplasma pneumoniae that cases showing clinical and radiological deterioration despite apporopriate antibiotic therapy

Exclusion criteria

Exclusion criteria: 1.the case has severe underlying disease or complication 2.Mycoplasma infection with extrapulmonary lesions 3.the case doctor has determined to be inappropriate to carry out the present study

Design outcomes

Primary

Measure	Time frame
symptom(fever,cough,respiratory rate,etc...)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026